Reagent for detecting nicotinamide adenine dinucleotide and detection kit thereof
By employing a two-step enzymatic cycle reaction involving alcohol dehydrogenase and a redox indicator, combined with standard curve detection, this method solves the problem of low sensitivity in NAD+ detection of samples such as plasma in existing technologies. It achieves high-sensitivity and low-cost NAD+ detection, applicable to a variety of samples.
Patent Information
- Application Number
- CN202411315167.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2026-03-20
AI Technical Summary
Existing technologies are difficult to use efficiently and cost-effectively to detect nicotinamide adenine dinucleotide in samples with low NAD+ content, such as plasma. Furthermore, existing methods have low sensitivity and high detection limits, making it difficult to meet the needs of various samples.
The reagent, consisting of alcohol dehydrogenase, phenazine methyl sulfate, thiazolyl blue tetrazolium bromide, and Bicine buffer, amplifies the NAD+ signal through a two-step enzymatic cycle and redox indicator mediation. Combined with a standard curve detection, it is suitable for plasma and other samples.
It achieves sensitivity ranging from micromolar to nanomolar levels, with a detection limit as low as 47.2 nm, enabling accurate detection of NAD+ content in cells, tissues, and plasma. It is simple to operate, low in cost, and has high throughput.
Smart Images

Figure CN121700033A_ABST
Abstract
Description
Technical Field
[0001] This application belongs to the field of medical biological detection technology, and in particular relates to a reagent and detection kit for detecting nicotinamide adenine dinucleotide. Background Technology
[0002] Nicotinamide adenine dinucleotide (NAD) + NAD+ is an important member of the pyridine nucleotide family. It is a classic coenzyme mediating various redox reactions and a cosubstrate for enzymes such as deacetylases (Sirtuins), poly-ADP-ribose polymerases (PARPs), and cyclic adenosine diphosphate ribose hydrolases. It plays a crucial role in energy metabolism, cell signal transduction, gene expression, and genome stability. + Levels of NAD+ decline with age, and this decline plays a crucial role in the development and progression of aging and age-related diseases. + Long-term metabolic imbalances can disrupt the body's physiological functions, leading to metabolic diseases, neurodegenerative diseases, and cancer. Recent studies have shown that increasing intracellular NAD+... + Levels of NAD+ are a promising approach to slowing aging and preventing age-related degenerative diseases. Although intracellular NAD+... + Metabolism is closely related to human health and disease, but NAD + The detection of content is extremely challenging.
[0003] Currently, high-performance liquid chromatography (HPLC), high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS), and liquid chromatography-mass spectrometry (HPLC-MS / MS) are the main methods for detecting NAD. + The commonly used method is HPLC. HPLC requires the addition of an internal standard to all samples, and is susceptible to signal shielding and inhibition by ionization, leading to NAD+ degradation. + Accurate quantification is difficult. HPLC-MS / HPLC-MS / MS methods combine the advantages of chromatography and mass spectrometry, significantly improving the sensitivity and specificity of detection. However, mass spectrometers are expensive, have high detection limits, are time-consuming, and have low throughput, which limits their application.
[0004] In addition, there are currently some commercially available NADs. + Quantitative reagent kit, based on NAD + The NAD content in the sample was determined by converting the NAD back to NADH and using the NADH standard curve. + Calculate the NAD content in the sample by considering the total amount and quantity of NADH. + This method has low sensitivity and a high detection limit, making it suitable for NAD3 assays in cells and tissues. + Samples with high NAD content are not suitable for use in plasma or other NAD+-rich samples. +Samples with low NADH content. Furthermore, NADH exhibits poor stability in solution and is difficult to preserve for extended periods.
[0005] Therefore, there is an urgent need for a highly sensitive NAD3 detector. + The detection kit is suitable for detecting NAD in various samples such as plasma, cells, and tissues. + Testing. Summary of the Invention
[0006] The purpose of this application is to provide a detection sensitivity range for NAD+. + With a detection limit as low as 47.2 nm, it can detect NAD in cells and tissues. + It can also detect the content of extracellular (such as plasma) NAD. + The content of [unspecified substance]; and the detection method described in this application is simple to operate, has high detection throughput, and low detection cost.
[0007] To achieve the above-mentioned objectives, the technical solution adopted in this application is as follows: In a first aspect, this application provides a reagent for detecting the content of nicotinamide adenine dinucleotide, comprising the following raw materials: ethanol, alcohol dehydrogenase, methyl phenazine sulfate (PMS), thiazolyl blue tetrazolium bromide (MTT), and buffer solution.
[0008] According to some embodiments of the reagent described in this application, each liter of the reagent comprises the following raw materials: 500-700 mmol ethanol, 1-3 mmol methyl phenazine sulfate, 0.3-0.7 mmol thiazolyl blue tetrazolium bromide, 1-2 μmol alcohol dehydrogenase, and buffer solution; The buffer solution includes Bicine buffer.
[0009] According to some embodiments of the reagent described in this application, the concentration of the Bicine buffer is 0.4-0.6 mol / L, for example 0.4 mol / L, 0.5 mol / L, or 0.6 mol / L.
[0010] According to some embodiments of the reagent described in this application, the pH of the Bicine buffer solution is 7.5-8.0.
[0011] According to some embodiments of the reagent described in this application, the concentration of Bicine in each liter of the reagent is 80-120 mM. Bicine is a derivative of the simple amino acid glycine.
[0012] A second aspect of this application provides a kit for detecting nicotinamide adenine dinucleotide content, comprising the reagents described in the first aspect of this application.
[0013] According to some embodiments of the kit described in this application, the kit further includes nicotinamide adenine dinucleotide standard, diluent, nicotinamide adenine dinucleotide extract, and neutralization solution.
[0014] According to some embodiments of the kit described in this application, the nicotinamide adenine dinucleotide standard is a 1500-1600 nM β-NAD solution. For example, 1500 nM, 1508 nM, 1520 nM, 1550 nM, 1560 nM, 1580 nM, and 1600 nM.
[0015] According to some embodiments of the kit described in this application, the diluent is artificial plasma.
[0016] According to some embodiments of the kit described in this application, each liter of artificial plasma comprises the following raw materials: 90-95 mmol sodium chloride, 8-10 mmol sodium bicarbonate, 18-20 mmol sodium carbonate, 2-4 mmol potassium chloride, 0.8-1.2 mmol potassium dihydrogen phosphate, 1-3 mmol magnesium chloride hexahydrate, 45-55 mmol HEPES buffer, 2-3 mmol calcium chloride dihydrate, 0.4-0.6 mmol sodium sulfate, and 35-45 g bovine serum albumin.
[0017] According to some embodiments of the kit described in this application, the pH of the artificial plasma is 7.0-7.4.
[0018] According to some embodiments of the kit described in this application, the nicotinamide adenine dinucleotide extract is an inorganic acid.
[0019] According to some embodiments of the kit described in this application, the inorganic acid includes hydrochloric acid.
[0020] According to some embodiments of the kit described in this application, the concentration of the inorganic acid is 0.2-0.4 mol / L, for example 0.2 mol / L, 0.3 mol / L, or 0.4 mol / L.
[0021] According to some embodiments of the kit described in this application, the neutralizing solution comprises an inorganic base.
[0022] According to some embodiments of the kit described in this application, the inorganic base includes KOH.
[0023] According to some embodiments of the kit described in this application, the concentration of the inorganic base is 0.2-0.4 mol / L, for example 0.2 mol / L, 0.3 mol / L, or 0.4 mol / L.
[0024] A third aspect of this application provides a method for using the reagent kit described in the second aspect of this application, comprising the following steps: (1) Use diluent to serially dilute nicotinamide adenine dinucleotide standard. Add nicotinamide adenine dinucleotide extract to the nicotinamide adenine dinucleotide standard and the serially diluted nicotinamide adenine dinucleotide, respectively, and incubate. After incubation, add neutralization solution, centrifuge, and take the supernatant for later use. (2) Add the reagent described in the first aspect of this application to the supernatant obtained in step (1), and continuously detect the absorbance of each supernatant at 565 nm; and construct a rectangular coordinate system with the concentration of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide as the abscissa and the enzyme catalytic reaction rate of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide as the ordinate. The slope of the straight line formed by the absorbance of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide at 565 nm and the measurement time is the enzyme catalytic reaction rate. Substitute the enzyme catalytic reaction rate into the rectangular coordinate system and connect the enzyme catalytic reaction rates corresponding to nicotinamide adenine dinucleotide standard and nicotinamide adenine dinucleotide dinucleotide at different concentrations to obtain a standard curve; (3) Add nicotinamide adenine dinucleotide extract to the sample and incubate. After incubation, add neutralization solution, centrifuge, take the supernatant, add the reagent described in the first aspect of this application, and continuously detect its absorbance at 565 nm. Substitute the slope of the straight line formed by absorbance and measurement time into the standard curve to obtain the concentration of nicotinamide adenine dinucleotide in the sample.
[0025] According to some embodiments of the method of using the kit described in this application, the concentration of the nicotinamide adenine dinucleotide standard is 1500-1600 nM, for example 1500 nM, 1508 nM, 1520 nM, 1550 nM, 1570 nM, 1580 nM, 1600 nM.
[0026] According to some embodiments of the method of using the kit described in this application, the gradient dilution includes performing gradient dilution in five stages. The concentration of the nicotinamide adenine dinucleotide diluted in the first stage is 750-800 nM, for example, 754 nM, 760 nM, 762 nM, 770 nM, 780 nM, 786 nM, and 800 nM; the concentration of the nicotinamide adenine dinucleotide diluted in the second stage is 350-400 nM, for example, 360 nM, 377 nM, 380 nM, and 400 nM; the concentration of the nicotinamide adenine dinucleotide diluted in the third stage is... The concentrations of the nicotinamide adenine dinucleotide diluents obtained from the fourth stage of dilution are 170-200 nM, for example, 170 nM, 180 nM, 188 nM, 193 nM, and 200 nM; the concentrations of the nicotinamide adenine dinucleotide diluents obtained from the fifth stage of dilution are 85-100 nM, for example, 85 nM, 90 nM, 94 nM, 96 nM, 98 nM, and 100 nM; and the concentrations of the nicotinamide adenine dinucleotide diluents obtained from the fifth stage of dilution are 42-50 nM, for example, 42 nM, 45 nM, 47 nM, 48 nM, and 50 nM.
[0027] According to some embodiments of the method of using the kit described in this application, the volume ratio of the added nicotinamide adenine dinucleotide extract to the nicotinamide adenine dinucleotide standard is (1-1.2):1, for example 1:1, 1.1:1, 1.2:1.
[0028] According to some embodiments of the method of using the kit described in this application, the volume ratio of the added nicotinamide adenine dinucleotide extract to the volume of the nicotinamide adenine dinucleotide dilution is (1-1.2):1, for example 1:1, 1.1:1, 1.2:1.
[0029] According to some embodiments of the method of using the kit described in this application, in step (1), the incubation includes the following steps: incubating at 55-65℃, for example, 55℃, 58℃, 60℃, 62℃, 65℃ for 8-12 min, for example, 8 min, 9 min, 10 min, 12 min; and then incubating at 0 to -5℃, for example, 0℃, -2℃, -3℃, -5℃ for 8-12 min, for example, 8 min, 9 min, 10 min, 12 min.
[0030] According to some embodiments of the method of using the kit described in this application, in step (1), a neutralizing solution is added until the pH of the solution is 7-7.4, for example 7, 7.1, 7.2, 7.4.
[0031] According to some embodiments of the method of using the kit described in this application, in step (2), the supernatant obtained in step (1) is added to the ELISA plate, the reagent is added to the supernatant, and the plate is stored in the dark for 4-8 minutes. The absorbance at 565 nm is detected using an ELISA reader with a detection temperature of 25°C. The detection is performed once every 1-2 minutes and continuously for 30-40 minutes.
[0032] According to some embodiments of the method of using the kit described in this application, in step (3), the volume ratio of the nicotinamide adenine dinucleotide extract to the test sample is (1-1.2):1, for example 1:1, 1.1:1, 1.2:1.
[0033] According to some embodiments of the method of using the kit described in this application, in step (3), the incubation includes the following steps: incubating at 55-65°C for 8-12 min, and then incubating at 0 to -5°C for 8-12 min.
[0034] According to some embodiments of the method of using the kit described in this application, in step (3), a neutralizing solution is added until the pH of the solution is 7-7.4, for example 7, 7.1, 7.2, 7.4.
[0035] According to some embodiments of the method of using the kit described in this application, in step (3), the supernatant is added to the ELISA plate, the reagent is added to the supernatant, and it is stored in the dark for 4-8 minutes. The absorbance at 565 nm is detected using an ELISA reader with a detection temperature of 25°C. The detection is performed once every 1-2 minutes and continuously for 30-40 minutes.
[0036] According to some embodiments of the method of using the kit described in this application, the sample includes serum, plasma, cell supernatant, cell lysate, tissue lysate, or urine.
[0037] The beneficial effects of the present invention are as follows: The reagent for detecting nicotinamide adenine dinucleotide content described in the present invention is based on a two-step enzymatic cycle reaction of alcohol dehydrogenase. Through the mediation of redox indicators, the signal of nicotinamide adenine dinucleotide is amplified, thereby improving its detection capability.
[0038] The kit described in this invention has a sensitivity range for the detection of nicotinamide adenine dinucleotide (NAD) from micromolar to nanomolar levels. The detection limit of the kit described in this application is as low as 47.2 nm, and it can detect NAD in cells and tissues. + It can also detect the content of extracellular (such as plasma) NAD. + The content of.
[0039] The reagent kit described in this invention is simpler to operate, provides accurate detection results, has high throughput, and is low in cost. This invention uses NAD+. +The extract directly extracts NAD from the sample. + Using NAD + As a standard, a standard curve is created to directly detect NAD in the sample. + The kit offers improved content, simpler operation, and more accurate results. Furthermore, this invention uses an albumin-containing solution as the standard diluent to simulate the environment of human tissue fluid, and NAD... + The activity of alcohol dehydrogenase in the standards was optimized, and the linearity and sensitivity of the standard curve were enhanced. Attached Figure Description
[0040] To more clearly illustrate the technical solutions in the embodiments of this application, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.
[0041] Figure 1 This is a diagram illustrating the mechanism of action of the kit described in this application for detecting nicotinamide adenine dinucleotide in human tissues. Figure 2 This is the standard curve diagram described in Embodiment 3 of this application; Figure 3 Scatter plot showing the relationship between the level of nicotinamide adenine dinucleotide in human plasma and age. Detailed Implementation
[0042] To make the technical problems, technical solutions, and beneficial effects of this application clearer, the following detailed description is provided in conjunction with embodiments. It should be understood that the specific embodiments described herein are merely illustrative and not intended to limit the scope of this application.
[0043] In this application, the term "and / or" describes the relationship between related objects, indicating that three relationships can exist. For example, A and / or B can represent: A existing alone, A and B existing simultaneously, or B existing alone. A and B can be singular or plural. The character " / " generally indicates that the preceding and following related objects have an "or" relationship.
[0044] In this application, "at least one" means one or more, and "more than one" means two or more. "At least one of the following" or similar expressions refer to any combination of these items, including any combination of single or multiple items. For example, "at least one of a, b, or c", or "at least one of a, b, and c", can both mean: a, b, c, ab (i.e., a and b), ac, bc, or abc, where a, b, and c can be single or multiple.
[0045] It should be understood that in the various embodiments of this application, the order of the above processes does not imply the order of execution. Some or all steps may be executed in parallel or sequentially. The execution order of each process should be determined by its function and internal logic, and should not constitute any limitation on the implementation process of the embodiments of this application.
[0046] The terminology used in the embodiments of this application is for the purpose of describing particular embodiments only and is not intended to be limiting of this application. The singular forms “a,” “the,” and “the” used in the embodiments of this application and the appended claims are also intended to include the plural forms unless the context clearly indicates otherwise.
[0047] The weights of the relevant components mentioned in the embodiments of this application can refer not only to the specific content of each component, but also to the proportional relationship between the weights of the components. Therefore, any scaling up or down of the content of the relevant components according to the embodiments of this application is within the scope disclosed in the embodiments of this application. Specifically, the mass described in the embodiments of this application can be a well-known unit of mass in the chemical industry, such as µg, mg, g, or kg.
[0048] Example 1 A reagent for detecting nicotinamide adenine dinucleotide content, wherein each liter of reagent comprises the following ingredients: 600 mmol ethanol, 2 mmol methyl phenazine sulfate, 0.5 mmol thiazolyl blue tetrazolium bromide, 1.4 μmol ethanol dehydrogenase, and 100 mmol of Bicine buffer with a concentration of 0.5 mol / L and a pH of 7.8.
[0049] The reagent for detecting nicotinamide adenine dinucleotide (NADP) content described in this invention is based on a two-step enzymatic cycle reaction of alcohol dehydrogenase. Through the mediation of a redox indicator, it amplifies the NADP signal, thereby improving its detection capability. Its mechanism of action is as follows: Figure 1 As shown.
[0050] Example 2 A kit for detecting nicotinamide adenine dinucleotide content includes the reagents described in Example 1, 1500-1600 nM β-NAD solution, artificial plasma, 0.3 mol / L inorganic acid, and 0.3 mol / L potassium hydroxide solution; Each liter of artificial plasma comprises the following ingredients: 92.4 mmol sodium chloride, 8.8 mmol sodium bicarbonate, 19.3 mmol sodium carbonate, 3.0 mmol potassium chloride, 1.0 mmol potassium dihydrogen phosphate, 1.5 mmol magnesium chloride hexahydrate, 50.1 mmol HEPES buffer, 2.6 mmol calcium chloride dihydrate, 0.5 mmol sodium sulfate, and 40 g bovine serum albumin. The pH of the artificial plasma is 7.4.
[0051] Example 3 Methods for detecting nicotinamide adenine dinucleotide levels in fresh human peripheral blood: (1) Sample preparation: Collect 5ml of fresh human peripheral blood, anticoagulate with lithium heparin, and within 30 minutes after blood collection, centrifuge at 2500g and 4℃ for 15 minutes to separate plasma; (2) The 1508 nM nicotinamide adenine dinucleotide standard was serially diluted using diluent to obtain diluents of 754 nM, 377 nM, 188.5 nM, 94.3 nM and 47.2 nM. Nicotinamide adenine dinucleotide extract was added to the nicotinamide adenine dinucleotide standard and the obtained diluents respectively. The volume ratio of the nicotinamide adenine dinucleotide extract to the diluent was 1:1. The nicotinamide adenine dinucleotide extract was incubated at 60°C for 10 min and then incubated at 0°C on an ice bath for 10 min. After the incubation was completed, neutralization solution was added to adjust the pH to 7.4. The mixture was centrifuged at 16000 g and 4°C for 10 min. The supernatant was then transferred to a new EP tube. (3) Add 50 μl of the supernatant obtained in step (2) to the corresponding wells of the ELISA plate, with two auxiliary wells for each sample. Then add 150 μl of the reagent described in Example 1 to each well and mix thoroughly. After that, store the ELISA plate at room temperature in the dark for 5 min. Then use an ELISA reader with a detection temperature of 25℃ to detect the absorbance at 565 nm. Detect once every 1-2 min for 30 min. Plot the concentrations of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide dinucleotide on the x-axis and the concentrations of nicotinamide adenine dinucleotide on the y-axis. A rectangular coordinate system was constructed with the enzyme catalytic reaction rate of the nicotinamide adenine dinucleotide standard and the serially diluted nicotinamide adenine dinucleotide dinucleotide as the ordinate. The slope of the straight line formed by the absorbance of the nicotinamide adenine dinucleotide standard and the serially diluted nicotinamide adenine dinucleotide dinucleotide and the measurement time was used as the enzyme catalytic reaction rate. The enzyme catalytic reaction rate was substituted into the rectangular coordinate system, and the enzyme catalytic reaction rates corresponding to the nicotinamide adenine dinucleotide standard and the nicotinamide adenine dinucleotide dinucleotide dinucleotide at different concentrations were connected to obtain the standard curve. (4) Add nicotinamide adenine dinucleotide extract to the sample to be tested, wherein the volume ratio of nicotinamide adenine dinucleotide extract to the sample to be tested is 1:1, incubate at 60°C for 10 min, then incubate at 0°C in an ice bath for 10 min, after the incubation is completed, add neutralization solution to adjust the pH to 7.4, centrifuge at 16000g and 4°C for 10 min to obtain the supernatant; (5) Add 50 μl of the supernatant obtained in step (4) to the corresponding wells of the ELISA plate, with two auxiliary wells for each sample. Then add 150 μl of the reagent described in Example 1 to each well and mix thoroughly. After that, store the ELISA plate at room temperature in the dark for 5 min. Then use an ELISA reader with a detection temperature of 25℃ to detect the absorbance at 565 nm. Detect once every 1-2 min, and continuously detect for 30 min. Substitute the slope of the linear relationship between absorbance and measurement time into the standard curve to obtain the concentration of nicotinamide adenine dinucleotide in the sample.
[0052] The method for detecting nicotinamide adenine dinucleotide (NADP) in fresh human peripheral blood described in this application is as follows: Twenty samples were randomly selected, with ages ranging from 20 to 60 years. Plasma was separated, and the concentration of nicotinamide adenine dinucleotide in the plasma samples was detected using the detection method described in Example 3 of this application. The detection results are shown in Table 1, and the scatter plot of the relationship between plasma nicotinamide adenine dinucleotide content and age is shown in the figure. Figure 3 As shown.
[0053] Table 1. NAD+ concentrations in 20 plasma samples Serial Number gender age sample NAD+ concentration (nM) 1 male 45 plasma 490.6 2 male 36 plasma 441.3 3 male 48 plasma 442.0 4 male 51 plasma 372.0 5 female 35 plasma 426.5 6 female 55 plasma 435.7 7 male 45 plasma 464.2 8 female 46 plasma 411.3 9 female 38 plasma 406.4 10 male 32 plasma 469.1 11 male 26 plasma 471.8 12 female 48 plasma 474.2 13 female 44 plasma 484.9 14 female 29 plasma 496.9 15 female 27 plasma 459.5 16 female 27 plasma 518.2 17 male 30 plasma 424.0 18 female 30 plasma 384.7 19 female 30 plasma 375.9 20 male 56 plasma 466.5 From Table 1 and Figure 3It can be seen that the level of nicotinamide adenine dinucleotide in the human body decreases with age, promoting aging and the occurrence of age-related diseases.
[0054] The above description is merely a preferred embodiment of this application and is not intended to limit this application. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of this application should be included within the protection scope of this application.
Claims
1. A reagent for detecting nicotinamide adenine dinucleotide content, characterized in that, It includes the following ingredients: ethanol, alcohol dehydrogenase, methyl phenazine sulfate, thiazolyl blue tetrazolium bromide, and buffer solution.
2. The reagent according to claim 1, characterized in that, Each liter of reagent contains the following ingredients: 500-700 mmol ethanol, 1-3 mmol methyl phenazine sulfate, 0.3-0.7 mmol thiazolyl blue tetrazolium bromide, 1-2 μmol ethanol dehydrogenase, and buffer solution; The buffer solution includes Bicine buffer; Preferably, the concentration of the Bicine buffer solution is 0.4-0.6 mol / L, and more preferably, the pH of the Bicine buffer solution is 7.5-8.
0.
3. A kit for detecting nicotinamide adenine dinucleotide content, characterized in that, Includes the reagent described in claim 1 or claim 2.
4. The reagent kit according to claim 3, characterized in that, The kit also includes nicotinamide adenine dinucleotide standard, diluent, nicotinamide adenine dinucleotide extract, and neutralization solution.
5. The reagent kit according to claim 4, characterized in that, The nicotinamide adenine dinucleotide standard is a 1500-1600 nM β-NAD solution; And / or, the diluent is artificial plasma; preferably, each liter of artificial plasma comprises the following ingredients: 90-95 mmol sodium chloride, 8-10 mmol sodium bicarbonate, 18-20 mmol sodium carbonate, 2-4 mmol potassium chloride, 0.8-1.2 mmol potassium dihydrogen phosphate, 1-3 mmol magnesium chloride hexahydrate, 45-55 mmol HEPES buffer, 2-3 mmol calcium chloride dihydrate, 0.4-0.6 mmol sodium sulfate, and 35-45 g bovine serum albumin; more preferably, the pH of the artificial plasma is 7.0-7.
4. And / or, the nicotinamide adenine dinucleotide extract is an inorganic acid, preferably, the inorganic acid includes hydrochloric acid, more preferably, the concentration of the inorganic acid is 0.2-0.4 mol / L; And / or, the neutralizing solution comprises an inorganic base, preferably KOH, and more preferably, the concentration of the inorganic base is 0.2-0.4 mol / L.
6. The method of using the reagent kit according to any one of claims 3-5, characterized in that, Includes the following steps: (1) Use diluent to serially dilute nicotinamide adenine dinucleotide standard. Add nicotinamide adenine dinucleotide extract to the nicotinamide adenine dinucleotide standard and the serially diluted nicotinamide adenine dinucleotide, respectively, and incubate. After incubation, add neutralization solution, centrifuge, and take the supernatant for later use. (2) Add the reagent described in claim 1 or claim 2 to the supernatant obtained in step (1), and continuously detect the absorbance of each supernatant at 565 nm; and construct a rectangular coordinate system with the concentration of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide as the abscissa and the enzyme catalytic reaction rate of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide as the ordinate. The slope of the straight line formed by the absorbance of nicotinamide adenine dinucleotide standard and serially diluted nicotinamide adenine dinucleotide at 565 nm and the measurement time is the enzyme catalytic reaction rate. Substitute the enzyme catalytic reaction rate into the rectangular coordinate system and connect the enzyme catalytic reaction rates corresponding to nicotinamide adenine dinucleotide standard and nicotinamide adenine dinucleotide dinucleotide at different concentrations to obtain a standard curve; (3) Add nicotinamide adenine dinucleotide extract to the sample to be tested, incubate, add neutralization solution after incubation, centrifuge, take the supernatant, add the reagent described in claim 1 or claim 2 and continuously detect its absorbance at 565 nm. Substitute the slope of the straight line formed by absorbance and measurement time into the standard curve to obtain the concentration of nicotinamide adenine dinucleotide in the sample.
7. The method of use according to claim 6, characterized in that, In step (1), the concentration of the nicotinamide adenine dinucleotide standard is 1500-1600 nM; And / or, the gradient dilution includes a five-stage gradient dilution, wherein the concentration of the nicotinamide adenine dinucleotide dilute obtained in the first stage is 750-800 nM, the concentration of the nicotinamide adenine dinucleotide dilute obtained in the second stage is 350-400 nM, the concentration of the nicotinamide adenine dinucleotide dilute obtained in the third stage is 170-200 nM, the concentration of the nicotinamide adenine dinucleotide dilute obtained in the fourth stage is 85-100 nM, and the concentration of the nicotinamide adenine dinucleotide dilute obtained in the fifth stage is 42-50 nM; And / or, the volume ratio of the added nicotinamide adenine dinucleotide extract to the nicotinamide adenine dinucleotide standard is (1-1.2):1; And / or, the volume ratio of the added nicotinamide adenine dinucleotide extract to the diluted nicotinamide adenine dinucleotide is (1-1.2):1; And / or, in step (1), the incubation includes the following steps: incubating at 55-65°C for 8-12 min, and then incubating at 0 to -5°C for 8-12 min; And / or, in step (1), add neutralizing solution until the pH of the solution is 7-7.
4.
8. The method of use according to claim 6, characterized in that, In step (2), the supernatant obtained in step (1) is added to the ELISA plate, the reagent is added to the supernatant, and the plate is stored in the dark for 4-8 minutes. The absorbance at 565 nm is detected using an ELISA reader with a detection temperature of 25℃. The detection is performed once every 1-2 minutes for 30-40 minutes. And / or, in step (3), the volume ratio of the nicotinamide adenine dinucleotide extract to the sample to be tested is (1-1.2):1; And / or, in step (3), the incubation includes the following steps: incubating at 55-65°C for 8-12 min, and then incubating at 0 to -5°C for 8-12 min; And / or, in step (3), add neutralizing solution until the pH of the solution is 7-7.
4.
9. The method of use according to claim 6, characterized in that, In step (3), the supernatant is added to the ELISA plate, the reagent is added to the supernatant, and the plate is stored in the dark for 4-8 minutes. The absorbance at 565 nm is detected using an ELISA reader with a detection temperature of 25°C. The detection is performed every 1-2 minutes for 30-40 minutes.
10. The method of use according to claim 6, characterized in that, The samples include serum, plasma, cell supernatant, cell lysate, tissue lysate, or urine.
